AngioDynamics Q2 Results Miss Estimates; Boosts FY24 Adj. EPS Outlook

From RTTNews:

Medical devices company AngioDynamics, Inc. raised its adjusted earnings guidance for the full year 2024, while trimming annual net sales outlook. For fiscal 2024, the company now projects adjusted earnings in the range of $0.35 to $0.42 per share on net sales between $320 million and $325 million, compared to previously expected $0.28 to $0.34 per share on net sales between $328 million and $333 million. The company reported a net loss of $29.05 million or $0.72 per share for the second quarter, wider than $8.47 million or $0.21 per share in the prior-year quarter. Excluding items, adjusted loss for the quarter was $0.05 per share, compared to adjusted income of $0.01 per share in the year-ago quarter. Net sales for the quarter decreased to $79.07 million from $85.43 million in the same quarter last year, missing the Street’s expectations.



Read more: AngioDynamics Q2 Results Miss Estimates; Boosts FY24 Adj. EPS Outlook